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OBJECTIVES We assessed the contribution of difference in duration of pulmonary venous and mitral flow
at atrial contraction (ARd-Ad) for prognostic stratification of patients with left ventricular
(LV) systolic dysfunction.
BACKGROUND Although pulmonary venous flow (PVF) variables may supplement mitral flow patterns in
evaluating left ventricular (LV) diastolic function, their value to the prognostic stratification
of patients has not been investigated.
METHODS Pulsed wave Doppler mitral and PVF velocity curves were recorded in 145 patients (mean age:
70 years) with LV systolic dysfunction secondary to ischemic or nonischemic cardiomyopathy
who were followed for 15 6 8 months. In 38% of patients, PVF signal was enhanced by the
intravenous (IV) administration of a galactose-based echo-contrast agent. Based on E-wave
deceleration time # or .130 ms and ARd-Ad, patients were grouped into restrictive (group
1, n 5 40), nonrestrictive with ARd-Ad $30 ms (group 2, n 5 55) and nonrestrictive with
ARd-Ad ,30 ms (group 3, n 5 50).
RESULTS During follow-up, 29 patients died from cardiac causes and 28 were hospitalized for
worsening heart failure (HF). On multivariate Cox model, ARd-Ad $30 ms provided
important prognostic information with regard to cardiac mortality and emerged as the single
best predictor of cardiac events (cardiac mortality, hospitalization). The 24-month cardiac
event-free survival was best (86.3%) for group 3; it was intermediate (37.9%) for group 2; and
it was worst (22.9%) for group 1 (p , 0.0002 group 1 vs. 3; p , 0.0005 group 2 vs. 3; p ,
0.0003 group 1 vs. group 2).
CONCLUSIONS Assessment of ARd-Ad exhibited an independent value in the prognostic evaluation of
patients with LV systolic dysfunction. Moreover, it contributed to identify patients at low,
intermediate and high risk of cardiac events. (J Am Coll Cardiol 2000;36:1295–302) © 2000
by the American College of Cardiology
It is well known that restrictive left ventricular (LV) filling,
as assessed by pulsed wave Doppler of the mitral flow,
usually identifies advanced heart disease associated with a
poor prognosis (1–3). However, because many patients with
LV systolic dysfunction display a nonrestrictive mitral flow
pattern (4–7), it would be desirable to identify other indices
able to stratify them in groups with different degree of risk
for cardiac death or hospitalization for worsening heart
failure (HF). In this respect, assessment of the difference in
duration of pulmonary venous and mitral flow at atrial
contraction (ARd-Ad) may provide valid information com-
plementary to that of mitral flow recordings. This study was
designed to determine the value of measuring ARd-Ad in
the prognostic stratification of patients with LV systolic
dysfunction.
METHODS
Patient selection. The study involved 145 consecutive
patients, prospectively examined owing to either ischemic or
nonischemic cardiomyopathies, undergoing echocardiogra-
phy for clinical purposes. Inclusion criteria were LV systolic
dysfunction, as defined by an ejection fraction (EF) #45%
and sinus rhythm. Excluded from the study were patients
with aortic or mitral organic valve disease, severe functional
mitral regurgitation according to the method of Helmcke et
al. (8), atrial fibrillation, postcardioversion atrial mechanical
failure, heart rate (HR) .100 beats/min, and those with
undetectable pulmonary venous flow (PVF) throughout the
cardiac cycle or absent PVF reversal wave.
Doppler echocardiographic examination. A complete
M-mode, two-dimensional and Doppler echocardiographic
study was carried out with an Acuson 128 XP-10 sector
scanner operating at 2.5 MHz. The same operator (F.L.D.)
performed all the examinations. Recordings were made with
the patient in left lateral decubitus during quiet respiration.
Continuous single-lead electrocardiogram (ECG) monitor-
ing was maintained during the study. The LV volumes and
EF were calculated from apical two- and four-chamber
views using the modified Simpson’s rule. The LV volume
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indices and LV mass index were also calculated (9). Left
atrial size was estimated in parasternal long-axis view.
Mitral regurgitation was graded as mild, moderate or severe
on the basis of maximal regurgitant jet area at color Doppler
examination obtained in two planes and expressed as a
percent of the left atrial area (8). Pulsed wave Doppler
mitral velocity curves were obtained from the apical four-
chamber view by positioning a 1–2-mm sample volume
between the tips of the mitral valve leaflets in diastole. The
PVF velocities from the right upper pulmonary vein were
acquired by placing a 2–3-mm sample volume 5 to 10 mm
proximal from its junction with the left atrium. The
maximal velocities of PVF recordings were averaged over
five consecutive cycles to minimize the known effects of
respiration on these variables. Mitral and PVF A-wave
durations were measured as close to the zero baseline as
possible from start to termination of flow at atrial contrac-
tion after the P wave on the simultaneously recorded ECG
(10). A display speed of 100 mm/s was used for measuring
mitral as well as PVF A-wave duration.
Contrast-enhanced study. After completion of the base-
line standard examination, patients with PVF tracings
inadequate for the above measurements were considered
eligible for contrast-enhanced study of PVF. Each patient
received 2.5 g of Levovist manually injected into an ante-
cubital vein at a concentration of 400 mg/ml and at an
infusion rate of 0.5 ml/s through a 20-gauge flexible
indwelling cannula (11). The pulsed Doppler analyses of
PVF velocity curves were repeated during left heart opaci-
fication. To avoid spectral distortion, quantitative analyses
of the velocity curves were performed as soon as signal
intensity had reached a clearly traceable envelope. The
Doppler flow signals were continuously recorded on video-
tape for at least 6 min after contrast injection.
Interobserver variability. Reproducibility of measure-
ments was assessed in 70 randomly selected patients with
optimal or near optimal PVF tracings by the physician who
performed the echocardiographic study and by an indepen-
dent observer who reviewed the tapes of both unenhanced and
contrast-enhanced-Doppler echocardiographic examinations.
Study groups. Study patients were categorized by their
mitral early wave deceleration time (EDT) in 1) restrictive
mitral flow pattern (EDT #130 ms) and 2) nonrestrictive
mitral flow pattern (EDT .130 ms) (12). To gain further
perspectives on the usefulness of Doppler echocardiographic
as prognostic indicators, nonrestrictive patients were subdi-
vided into two groups on the basis of mitral and PVF
velocity patterns. First, they were grouped based on
ARd-Ad ($30 ms or ,30 ms). Next, they were separated
according to mitral early-to-atrial (E/A) wave ratio: E/A
.1 (normalized) and E/A #1 (impaired relaxation).
Follow-up data. The patients were followed from 1 to 24
months (mean 15 6 8 months; median 16 months) after the
index Doppler echocardiogram. End points were cardiac
mortality, cardiac events (including cardiac mortality plus
hospitalization for worsening HF) and HF events (cardiac
events excluding sudden death). Deaths due to end-stage
HF were defined as those occurring in hospital as a result of
refractory progressive HF. Only one event was counted in
each patient. If a patient died after being previously hospi-
talized and regularly discharged, the event was considered as
death. The follow-up data were obtained monthly by
regular visits, through telephone calls, from local authority
registry, and from hospital records.
Statistical analyses. Data were expressed as mean values 6
1 SD. Comparisons among clinical, instrumental and Dopp-
ler echocardiographic variables were analyzed with chi-
square test for categorical variables and one-way analysis of
variance (ANOVA) for numerical variables (multiple com-
parisons were performed according to Bonferroni test in
case of significant F value). To calculate survival and event
rates in the patient population, life tables of survival were
obtained by using the Kaplan-Meier method (Product-
Limit Estimate). In assessing the impact of HF events,
sudden cardiac death was treated as censored observation.
Differences of survival curves were tested with Mantel-Cox
statistic log-rank analysis. The impact of demographics,
New York Heart Association (NYHA) functional class, LV
EF, LV mass, left atrial dimension, pulmonary artery
systolic pressure and selected mitral and PVF variables were
all analyzed by Cox proportional-hazards regression analysis
(BMDP 2L, Department of Biomathematics, University of
California, Los Angeles, revised 1990). Multivariate Cox
proportional-hazards regression analysis (toward stepwise
procedure) was used to investigate whether the following
variables were independent predictors of survival and event
rates: age, gender, NYHA functional class, LV EF, LV mass,
mitral regurgitation, restrictive mitral filling pattern, E/A wave
ratio .1, systolic-to-diastolic PVF wave ratio, ARd-Ad and
pulmonary artery systolic pressure. The above variables were
treated as dichotomous variables. Interobserver variability was
tested by the Bland and Altman method (13).
RESULTS
Patient characteristics. Mean age of the study population
was 70 years (range 42 to 86; median 71 years). Coronary
artery disease was the etiology of LV systolic dysfunction in
70% of patients as assessed by coronary angiography or by a
Abbreviations and Acronyms
ARd-Ad 5 difference in duration of pulmonary venous
and mitral flow at atrial contraction
E/A 5 early-to-atrial wave ratio
EDT 5 early wave deceleration time
EF 5 ejection fraction
HF 5 heart failure
HR 5 heart rate
LV 5 left ventricular
NYHA 5 New York Heart Association
PVF 5 pulmonary venous flow
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history of prior myocardial infarction. Mean LV EF was
31 6 7%. Forty-six patients (32%) were in NYHA func-
tional class I, 48 (33%) in class II, 38 (26%) in class III and
13 (9%) in class IV (Table 1).
Enhancement of pulmonary venous flow. Out of 145
patients, well-defined PVF Doppler tracings of antegrade and
reversal wave were obtained in 110 (76%) and 90 (62%) of
patients, respectively. In 55 patients (38%), Levovist was
administered to enhance poor PVF Doppler signals. After
contrast, all patients had enhancement of PVF Doppler sig-
nals. Optimal or near optimal envelope tracings were achieved
for antegrade and retrograde waves in 142 (98%) and 140
(97%) patients, respectively (Fig. 1). In patients with poorly
defined envelope recordings after contrast enhancement, PVF
wave velocities and the duration of reversal A-wave were
obtained by consensus. The interobserver variability in patients
not submitted to contrast enhancement and in those who
received the medium is shown in Table 2.
Figure 1. Pulsed Doppler mitral flow velocity (left panel) and contrast-enhanced pulmonary venous flow velocity (right panel) in a patient with LV systolic
dysfunction. Mitral A-wave duration (measured from the start of flow until flow ceases) was 125 ms. Pulmonary vein atrial reversal duration (from onset
to the cessation of reversed flow) was 175 ms. The difference was 50 ms. Assessment of pulmonary venous flow variables was accomplished after venous
contrast administration.
Table 1. Doppler Echocardiographic Variables in Patients Grouped According to Pulmonary
Venous and Mitral Flow Indices
Variable
Group 1
(n 5 40)
Group 2
(n 5 55)
Group 3
(n 5 50)
Age (yrs) 67 6 10 73 6 9‡ 69 6 10
% Women 28 31 36
Coronary artery disease (%) 58 65 64
HR (beats/min) 88 6 8 74 6 12‡ 71 6 12**
NYHA functional class III–IV (%) 75 27‡‡ 12**
LVEDVi (ml/m2) 140 6 39 118 6 36‡ 122 6 28*
LVESVi (ml/m2) 106 6 33 81 6 27‡ 80 6 23**
LVEF (%) 25 6 7 32 6 6‡ 35 6 6**
LV mass index (g/m2) 164 6 40 159 6 32 149 6 30
LAi (mm/m2) 28.6 6 2.5 26.4 6 3.1‡ 25.5 6 2.7**
Mitral regurgitation .11 (%) 40 13‡ 7**
E wave (cm/s) 110 6 18 82 6 22‡ 66 6 20**§
A wave (cm/s) 46 6 19 86 6 23‡ 85 6 21**
E/A ratio 2.9 6 1.5 1 6 0.4‡ 0.8 6 0.4**
EDT (ms) 115 6 12 198 6 41‡ 217 6 35**†
Ad (ms) 112 6 12 130 6 15‡ 148 6 14**§
AR wave (cm/s) 36 6 11 33 6 7 29 6 8
ARd (ms) 176 6 20 171 6 18 158 6 18**§
S wave (cm/s) 37 6 14 56 6 14‡ 58 6 10**
D wave (cm/s) 67 6 13 51 6 15‡ 41 6 12**
S/D ratio 0.6 6 0.2 1.2 6 0.4‡ 1.5 6 0.4**§
SFvti (%) 38 6 7 56 6 11‡ 60 6 10**†
ARd-Ad (ms) 63 6 19 43 6 12‡ 10 6 15**§
PASP (mm Hg) 59 6 11 43 6 12‡ 39 6 15**
Group 1: restrictive; Group 2: nonrestrictive with ARd-Ad $30 ms; Group 3: nonrestrictive with ARd-Ad ,30 ms.
*p , 0.05 Group 3 vs. Group 1; **p , 0.01 Group 3 vs. Group 1; †p , 0.05 Group 3 vs. Group 2; §p , 0.01 Group 3 vs.
Group 2; ‡p , 0.01 Group 2 vs. Group 1; ‡‡p , 0.001 Group 2 vs. Group 1.
LVEDVi 5 LV end-diastolic volume index; LVESVi 5 LV end-systolic volume index; LAi 5 left atrial index; S wave 5
systolic wave peak velocity; D wave5 diastolic wave peak velocity; SFvti 5 systolic fraction of time-velocity integrals; PASP 5
pulmonary artery systolic pressure.
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Outcome study. During follow-up, 30 patients (21%)
died, and 28 (19%) were hospitalized for worsening HF and
were discharged alive. One patient died of a noncardiac
cause. Of the 29 cardiac deaths, 11 occurred suddenly (38%)
and 18 (62%) were due to progressive HF. In the entire
study group, sensitivity and specificity of restrictive mitral
flow, ARd-Ad $30 ms and E/A .1 in predicting clinical
events are illustrated in Figure 2.
Seven variables were predictors of cardiac death on
univariate analysis. In descending order of power, they were
NYHA class III–IV; ARd-Ad $30 ms; age .70 years;
more than mild mitral regurgitation; LV EF ,25%; pul-
monary artery systolic pressure .50 mm Hg; and restrictive
mitral flow. By univariate analysis, an increased ARd-Ad
was the most powerful predictor of cardiac death or hospi-
talization for worsening HF (Table 3), whereas restrictive
mitral pattern was associated with an increased risk of HF
events, followed by NYHA functional class III–IV;
ARd-Ad $30 ms; pulmonary artery systolic pressure
.50 mm Hg; PVF systolic-to-diastolic velocity ratio ,1;
LV EF ,25%; HR .80 beats/min; more than mild mitral
regurgitation; E/A ratio .1; increased left atrial dimension;
and increased LV mass.
On multivariate analysis, increased ARd-Ad was among
predictors of cardiac mortality, along with age .70 years,
LV EF ,25%, and advanced NYHA functional class. An
ARd-Ad $30 ms proved to be the best predictor of fatal
outcome or hospitalization for worsening HF, followed by
LV mass .125 g/m2, older age, rapid HR, and NYHA
functional class III–IV. When freedom from HF events was
analyzed, several Doppler and echocardiographic variables
(i.e., increased ARd-Ad, restrictive mitral flow, E/A ratio
.1, and increased LV mass) were found to be predictive of
adverse outcome (Table 4).
Study group analyses. Characteristics of the study patients
in the restrictive and nonrestrictive groups, classified ac-
cording to ARd-Ad $ or ,30 ms, are displayed in Table 1.
The rates of survival free from cardiac mortality, event-free
survival and freedom from HF events in the three groups are
illustrated in Figure 3. Of note, the three Kaplan-Meier
curves were clearly discernible and exhibited statistically
significant differences at Mantel-Cox analysis for both
cardiac event-free survival and freedom from HF events.
When patients were stratified according to restrictive,
nonrestrictive with E/A .1, and nonrestrictive with E/A
#1 patterns, statistical significance for survival free from
cardiac mortality was reached only in the comparison
between restrictive and nonrestrictive groups (p , 0.05),
Figure 2. Bar graph showing the sensitivity (solid bars) and the specificity
(open bars) of restrictive mitral flow pattern (panel A), of ARd-Ad
$30 ms (panel B) and E/A .1 (panel C) in predicting clinical events.
Table 2. Interobserver Variability in Patients With Optimal or
Near Optimal Pulmonary Venous Flow Velocity Recordings
Unenhanced
tracings
Contrast-enhanced
tracings
S wave (cm/s) 5 6 7 4 6 7
D wave (cm/s) 5 6 7 5 6 8
AR wave (cm/s) 4 6 6 3 6 4
ARd (ms) 12 6 14 6 6 8
ARd-Ad (ms) 12 6 15 7 6 9
Data are expressed as mean 6 standard deviation. No significant differences between
the two observers were shown at Bland and Altman analysis.
S wave 5 systolic wave peak velocity; D wave 5 diastolic wave peak velocity.
Table 3. Predictors of Cardiac Events (Cardiac Death or
Hospitalization for Worsening Heart Failure) as Assessed by
Univariate Cox Model
Predictive variable
Chi
square p Value
ARd-Ad $30 ms 24.93 0.0001
Restrictive pattern 20.71 0.0001
NYHA functional class III–IV 19.95 0.0001
PASP .50 mm Hg 17.84 0.0001
S/D ratio ,1 16.04 0.0001
HR .80 beats/min 12.18 0.0005
Mitral regurgitation 9.01 0.0027
LV EF ,25% 8.80 0.0030
LAi .27 mm/m2 8.34 0.0039
E/A ratio .1 7.54 0.0060
Age .70 yrs 6.78 0.0092
LV mass .125 g/m2 4.53 0.0332
PASP 5 pulmonary artery systolic pressure; S/D ratio 5 systolic-to-diastolic wave
ratio; LAi 5 left atrial index.
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whereas no statistical difference was found between nonre-
strictive patients with E/A .1 or #1. For cardiac event-free
survival and freedom from HF events, the nonrestrictive
group with E/A .1 and that with E/A #1 showed broadly
overlapped curves, while the two curves were clearly dis-
cernible and statistically different (p , 0.0001) from that of
the restrictive group. Accordingly, no significant differences
emerged between nonrestrictive groups for both cardiac
event-free survival and freedom from HF events.
DISCUSSION
This study showed that increased ARd-Ad may be clinically
relevant to patients with LV systolic dysfunction. Although
less specific than the restrictive pattern, this abnormality
exhibited a higher sensitivity in predicting clinical events.
On multivariate analysis, ARd-Ad $30 ms was indepen-
dently associated with both cardiac mortality and HF
events, and it was the most powerful predictor of cardiac
events. Additionally, the association of a nonrestrictive
physiology with ARd-Ad $30 ms allowed us to identify a
group with a prognostic outcome intermediate between
patients with restriction and those with nonrestrictive pat-
tern without increased ARd-Ad.
Prognostic significance of LV diastolic parameters. The
clinical interest of the abnormalities in diastolic function has
been recognized as they are linked to both the symptom
status and the outcome of patients with LV systolic dys-
function (2,14). In particular, several studies have shown
that Doppler-derived mitral flow variables are important
indicators of cardiac mortality and worsening HF in various
cardiac diseases (13,15–24). In the majority of previous
studies carried out in patients with LV systolic dysfunction
secondary to either ischemic or idiopathic dilated cardiomy-
opathy, restrictive mitral flow was independently associated
with a poor outcome. Moreover, the restrictive pattern
identified a subset of patients with higher mortality
(13,18,20–24).
Recently, novel approaches have been developed to im-
prove Doppler assessment of LV diastolic function (2).
Similarly to E/A .1 in LV dysfunction, a PVF reversal
wave exceeding mitral A-wave duration at atrial contraction
was associated with elevated LV filling pressure (25–29).
However, ARd-Ad has the advantage of being less affected
by factors such as age, load and the degree of mitral
regurgitation with little overlap of its values between pa-
tients with and without elevated LV filling pressures (29–
33). Therefore, consideration of this parameter may provide
clinically relevant information that supplements information
obtained from mitral flow velocity tracings. In this study,
the high sensitivity of ARd-Ad $30 ms in predicting
adverse outcome is probably related to its ability to pick up
a wide range of patients—either restrictive or nonrestric-
tive—more prone to the occurrence of clinical events at
follow-up.
Although the nonrestrictive LV filling was associated
with better NYHA functional class and LV EF than was the
restrictive pattern, at variance from other studies (18,20–
23), a sizable number of patients in this category (30%) had
adverse events at follow-up. This probably derives from the
characteristics of our study population, mainly elderly pa-
tients with ischemic cardiomyopathy. Indeed, the age dif-
ference between our group (70 years) and those of previous
studies (with a mean age ranging between 39 and 61 years)
may help explain the large number of events among patients
in the nonrestrictive category (13,18–23).
Finally, in addition to the influence of clinical, LV
Table 4. Predictors of Clinical Events at Multivariate Cox Models
Predictive variable
Chi
square p Value
Relative
risk
Confidence
intervals
Independent predictors of cardiac mortality
NYHA functional class III–IV 9.54 0.002 2.02 0.94–4.35
Age .70 yrs 6.88 0.009 3.33 1.42–7.85
LV EF ,25% 5.06 0.025 2.38 1.12–5.04
ARd-Ad $30 ms 4.93 0.026 2.96 1.01–8.63
Independent predictors of cardiac events
ARd-Ad $30 ms 24.93 0.000 3.76 1.65–8.56
NYHA functional class III–IV 10.60 0.001 1.57 0.86–2.87
Age .70 yrs 6.50 0.011 2.29 1.32–4.00
HR .80 beats/min 4.83 0.028 1.82 1.04–3.19
LV mass .125 g/m2 4.20 0.041 2.33 1.04–5.19
Independent predictors of HF events
Restrictive pattern 29.33 0.001 5.41 2.10–13.91
ARd-Ad $30 ms 11.04 0.001 5.56 1.84–16.84
Age .70 yrs 8.31 0.004 2.59 1.34–5.00
NYHA functional class III–IV 8.20 0.004 2.14 1.00–4.57
LV mass .125 g/m2 6.92 0.009 3.56 1.41–9.03
E/A ratio .1 5.68 0.017 4.17 1.45–11.98
PASP .50 mm Hg 4.97 0.026 3.08 1.41–6.69
PASP 5 pulmonary artery systolic pressure; LAi 5 left atrial index.
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systolic and diastolic parameters, an independent association
was observed between increased LV mass and outcome.
Although this may also partly account for the large number
of events in the nonrestrictive subset, further investigations
are needed to better assess its role as predictor of adverse
outcome in LV systolic dysfunction.
Subgrouping of nonrestrictive patients. Because many
patients with LV systolic dysfunction exhibited a nonre-
strictive mitral flow pattern, it was interesting to classify
them further in groups with intermediate and low risk.
Accordingly, a useful categorization was accomplished using
a cutoff of 30 ms in ARd-Ad (26,29). Our results provide
evidence that it is possible to classify nonrestrictive patients
into two groups significantly different from a prognostic
standpoint. Despite similar degree of systolic dysfunction
and functional class, nonrestrictive patients with ARd-Ad
$30 ms showed a higher frequency of events at follow-up as
opposed to those with nonrestrictive filling without that
difference.
The observation of a nonrestrictive group with an inter-
mediate risk of clinical events is in line with that made by
Pozzoli et al. (13), who found that in a population with
nonrestrictive flow a change in mitral flow pattern toward
restriction during dynamic preload variations was associated
with a worse prognosis compared to those with stable
nonrestrictive flow. Results from the same study and those
of a recent one (34) confirm a limited value of mitral E/A
ratio in the prognostic assessment of nonrestrictive patients
with LV dysfunction. Indeed, when E/A #1 and E/A .1
were employed to categorize our series nonrestrictive pa-
tients, the resulting two groups were not significantly
different for occurrence of both cardiac events and HF
events at follow-up. The high dependence of mitral flow
velocity patterns to varying patient conditions, such as load,
age and heart rate, may contribute to justify this observation
(2,35–37). Moreover, severely impaired LV relaxation may
account for blunting of early mitral flow with E/A #1
despite increased LV filling pressure (38).
The mechanism whereby nonrestrictive patients with
increased ARd-Ad were associated with a large number of
events at follow-up is not clear. Of interest, the number of
sudden deaths (presumably arrhythmic) in our series was
rather elevated in patients with this pattern. Hence, coex-
isting intrinsic myocardial abnormalities (e.g., myocardial
fibrosis, responsible for either the elevation of LV diastolic
pressure or the propensity to fatal arrhythmias) may be the
substrate of this finding.
Study limitations. The major limitation of the study is
the lack of simultaneous hemodynamic measurement with
Doppler examination. However, the data from previous
investigations are strong enough to support the association
between elevated LV end-diastolic pressure and increased
ARd-Ad; this may allow us to categorize patients according
to this index (25,26). Although the deceleration time of
early mitral flow was significantly different in the two groups
of nonrestrictive patients, cutoff values based on the relative
duration of atrial flow at pulmonary veins and mitral valve
seem preferable as they are associated with clear-cut hemo-
dynamic reference values regardless of the pattern.
Another limitation is that Doppler echocardiography was
not used to perform quantitative assessment of mitral
regurgitant jets (39). Even if this could have reduced the
potential value of mitral regurgitation as a predictor of
adverse events, methods to evaluate the regurgitant orifice
area are not yet routine practice in our busy echocardio-
graphic laboratory. Measurement of ventricular volumes by
two-dimensional echocardiography has also been criticized.
Although LV volume measurements were obtained by the
biplane Simpson’s rule, detection of LV myocardial con-
tours without tissue harmonic imaging or contrast-
enhancement limited the image acquisition and accuracy of
volume determination. Finally, because not all patients
Figure 3. Twenty-four-month estimates of survival and event rates after
index Doppler echocardiogram by Kaplan-Meier analysis. Groups were
stratified according to restrictive mitral flow (group 1), nonrestrictive mitral
flow with a ARd-Ad $30 ms (group 2) and nonrestrictive mitral flow with
ARd-Ad ,30 ms (group 3). (A) Rates of survival free from cardiac
mortality. (B) Rates of cardiac event-free survival. (C) Rates of freedom
from heart failure.
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returned to our laboratory for a follow-up Doppler echocar-
diographic study, the evolution of mitral and PVF patterns and
their modifications by medical therapy were not considered.
Conclusions. The major finding of the study is that an
increased ARd-Ad $30 ms has an additive value in pre-
dicting prognosis of patients with LV systolic dysfunction.
Particularly, this measure in asymptomatic nonrestrictive
patients with LV dysfunction can aid clinical decision
making by separating patients into those with different risk
of clinical events at follow-up.
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